Xenetic Biosciences, Inc. last reported quarterly results on Aug 7, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $660,601 (+12.0% year over year) and diluted EPS of -$0.41. It usually reports 38–72 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 13, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 38–72 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 7, 2026
38 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1
+12.0%
|
-1
-35.0%
|
-0.41
+8.9%
|
|
May 13, 2026
43 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1
+36.0%
|
-0
+49.5%
|
-0.20
+66.1%
|
|
Mar 13, 2026
72 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1
+18.1%
|
-1
+45.1%
|
-0.27
+61.0%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1
+67.2%
|
-1
-16.8%
|
-0.33
-17.9%
|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1
-18.8%
|
-1
+45.9%
|
-0.45
+45.8%
|
|
May 14, 2025
44 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
1
+16.1%
|
-1
+24.4%
|
-0.59
+24.4%
|
|
Nov 13, 2024
44 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
1
+0.5%
|
-0
+58.6%
|
-0.28
+59.4%
|
|
Aug 14, 2024
45 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Framingham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534525
- Former names
- General Sales & Leasing, Inc. (until Jan 10, 2014); GENERAL AIRCRAFT INC. (until Feb 12, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.